A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)

Background

REMAP-CAP is an international adaptive platform trial in Community-Acquired Pneumonia (CAP). CAP is a syndrome where individuals who have not been recently hospitalised develop an acute infection of the lungs. Bacterial and viral infections are responsible for the vast majority of CAP. CAP that is severe enough to require admission to an Intensive Care Unit (ICU) is associated with substantial risk of mortality.

Patients with severe pneumonia routinely receive multiple treatments at the same time – as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don’t always know which treatment option is the better one, as individuals or groups of individuals may respond differently.

This trial aims to help doctors understand which treatments work best.

Design

This trial will use a trial design known as a REMAP, a Randomised, Embedded, Multifactorial, Adaptive Platform trial. REMAP-CAP evaluates multiple interventions simultaneously in critically ill patients. The trial is modular so that new domains (groups of similar treatment options) can be added over time. Conclusions can be drawn as soon as enough data has been collected about a specific treatment. This is particularly helpful for pandemic research because researchers can evaluate which treatments work best and how different treatments interact with each other more quickly.

Over time, this REMAP will help to determine and continuously update the optimal set of treatments for community-acquired pneumonia and other, similar infections.

More information about REMAP-CAP and taking part in the trial can be found on the REMAP-CAP UK Website.

The privacy notice for this trial can be downloaded here.

Key information